LCD-L37891
Document details
Summary
The update to the MolDX policy for Envisia™ and Veracyte™ tests will enable more accurate billing for idiopathic pulmonary fibrosis diagnostic services. This will likely enhance reimbursement rates foEnvisia™ and Veracyte™ tests now enhance billing accuracy.
Affected codes
ICD-10-CM
Affected specialty
Pulmonology alerts →Source document
https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=37891&ver=24CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.
Related alerts
4Policy FDA-NDA207356 · Pulmonology
Arikayce (amikacin liposomal inhalation suspension) received FDA approval in September 2018 as an inhaled orphan drug for refractory Mycobacterium avium complex (MAC) lung disease, administered via a
View alertPolicy LCD-L39711 · Pulmonology
The finalized LCD L39711 pertains to the use of molecular biomarkers for risk stratification of indeterminate pulmonary nodules following bronchoscopy. This LCD is active and will be effective startin
View alertPolicy LCD-L39658 · Pulmonology
The final LCD L39658 addresses the use of molecular biomarkers for risk stratification of indeterminate pulmonary nodules following bronchoscopy, effective from June 18, 2026. Healthcare providers in
View alertPolicy FDA-NDA019193 · Pulmonology
Provocholine (Methacholine Chloride) is an injectable drug likely to receive a specific J-code for billing. As a Part B candidate, it may be eligible for pass-through payment or reimbursed at ASP+6%.
View alert